Shuttle Pharmaceuticals falls sharply amid market gains
Shuttle Pharmaceuticals Holdings Inc. saw a significant decline of 23.83% as it crossed below its 5-day SMA, indicating a bearish trend.
The stock's drop occurred despite the broader market's positive performance, with the Nasdaq-100 and S&P 500 both showing gains. This suggests a sector rotation, where Shuttle Pharmaceuticals is moving against the overall market trend.
Investors may need to reassess their positions in Shuttle Pharmaceuticals as the stock's performance diverges from the market, potentially indicating underlying issues within the company.
Trade with 70% Backtested Accuracy
Analyst Views on SHPH
About SHPH
About the author
Shuttle Pharmaceuticals Announces Public Offering of Shares
- Funding Size: Shuttle Pharmaceuticals has entered into a securities purchase agreement to issue 2.24 million shares of common stock and pre-funded warrants for an aggregate gross proceeds of approximately $3.50 million, indicating a significant capital market financing need.
- Offering Details: The public offering is expected to close around March 9, 2026, suggesting the company is seeking financial support for future business development, even as its stock price fell by 13.92% in premarket trading.
- Market Reaction: Following the announcement of the offering, Shuttle Pharmaceuticals' stock price dropped to $0.7476 in premarket trading, reflecting a cautious market sentiment regarding the financing, which may impact investor confidence.
- Strategic Implications: This financing will provide essential capital to address operational costs and R&D expenditures, and while the market response is negative, it may ultimately support the company's long-term growth objectives.
Shuttle Pharmaceuticals (SHPH) Shares Surge 158% to $4.21 Amid AI-Driven Oncology Pipeline Interest
- Stock Surge: Shuttle Pharmaceuticals' shares soared 158% in pre-market trading to $4.21, reflecting strong investor interest in its oncology pipeline and signaling confidence in the company's growth potential.
- AI Integration: Recent regulatory approval for AI-based prescriptions in Utah highlights the strategic importance of Shuttle's use of the Molecule.ai platform in drug discovery, which is expected to reduce costs and accelerate the identification of new drug candidates.
- Pipeline Overview: The company's pipeline includes investigational candidates like Ropidoxuridine (ROPES) and SP-2, aimed at enhancing radiation therapy effectiveness and working alongside immunotherapies to strengthen tumor response, supporting precision medicine initiatives.
- Stock Performance History: SHPH has traded between $1.52 and $25.25 over the past year, with the latest data showing a closing price of $1.63 on January 16, 2026, up 10.14% from the previous day.
Shuttle Pharma Applauds Utah's AI Prescription Refill System, Enhancing Healthcare Efficiency
- AI Prescription Innovation: Utah becomes the first state in the U.S. to allow AI systems to authorize prescription refills without direct physician involvement, marking a significant advancement in reducing healthcare costs, eliminating delays, and expanding access to care.
- Enhanced Drug Discovery Efficiency: Shuttle Pharma's Molecule.ai platform applies AI technology to significantly shorten the time to identify viable drug candidates and reduce the costs of failed experiments, transforming what once took months of manual experimentation into just days, thereby greatly improving R&D efficiency.
- Regulatory and Safety Measures: The Molecule.ai platform incorporates uncertainty quantification and human-in-the-loop workflows to ensure expert oversight at critical decision points, enhancing the safety and reliability of AI in drug discovery.
- Future Policy Implications: Results from Utah's AI prescription pilot program will guide future state and federal AI policies, potentially serving as a national model for high-stakes AI regulation in healthcare, driving demand for robust AI platforms in the industry.
Shuttle Pharma Names Christopher Cooper as Acting CFO
CFO Resignation: Timothy Lorber has resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. effective November 21, 2025.
Interim CFO Appointment: Christopher Cooper, the current Interim Chief Executive Officer, has taken over the role of Chief Financial Officer.
Search for Permanent CFO: The company is actively searching for a permanent Chief Financial Officer to fill the position.
Disclaimer: The views expressed in the article do not necessarily reflect those of Nasdaq, Inc.
LexinFintech Shares Surge Over 15%; Check Out 20 Stocks Making Moves in Premarket Trading
LexinFintech Holdings Performance: LexinFintech Holdings Ltd reported a significant increase in quarterly earnings, rising to 43 cents per share from 28 cents a year ago, despite a drop in sales to $367.580 million from $521.851 million. The stock surged 15.3% in pre-market trading.
Other Gainers in Pre-Market Trading: Several stocks saw notable increases in pre-market trading, including Inspire Veterinary Partners Inc (+54.4%), VisionSys AI Inc (+43.4%), and JX Luxventure Group Inc (+36.2%).
Losers in Pre-Market Trading: Conversely, stocks like Clearside Biomedical Inc (-50.3%), Shuttle Pharmaceuticals Holdings Inc (-15%), and XChange TEC.INC (-14%) experienced significant declines in pre-market trading.
Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both gainers and losers, along with specific percentage changes.
What Caused the Overnight Surge in Shuttle Pharmaceuticals (SHPH) Stock?
Stock Performance: Shuttle Pharmaceuticals Holdings Inc. (SHPH) saw a 27.87% increase in after-hours trading, reaching $2.34, despite closing down 7.58% at $1.83 during regular trading. The stock is down 91.4% year-to-date.
S-1 Registration Statement: The company filed a Form S-1 registration statement with the SEC for the resale of 625,156 common shares linked to a pre-funded warrant with a $0.001 exercise price.
Private Placement: Shuttle Pharmaceuticals completed a private placement on November 4, generating approximately $2.5 million in gross proceeds from an accredited investor, with WestPark Capital Inc. acting as the placement agent.
Market Capitalization: As of Monday, the company had 1,603,285 outstanding shares and a market capitalization of $2.93 million, with the filing indicating that it will not receive proceeds from the selling stockholder’s share sales.
Shuttle Pharmaceuticals Announces Public Offering of Shares
- Funding Size: Shuttle Pharmaceuticals has entered into a securities purchase agreement to issue 2.24 million shares of common stock and pre-funded warrants for an aggregate gross proceeds of approximately $3.50 million, indicating a significant capital market financing need.
- Offering Details: The public offering is expected to close around March 9, 2026, suggesting the company is seeking financial support for future business development, even as its stock price fell by 13.92% in premarket trading.
- Market Reaction: Following the announcement of the offering, Shuttle Pharmaceuticals' stock price dropped to $0.7476 in premarket trading, reflecting a cautious market sentiment regarding the financing, which may impact investor confidence.
- Strategic Implications: This financing will provide essential capital to address operational costs and R&D expenditures, and while the market response is negative, it may ultimately support the company's long-term growth objectives.
Shuttle Pharmaceuticals (SHPH) Shares Surge 158% to $4.21 Amid AI-Driven Oncology Pipeline Interest
- Stock Surge: Shuttle Pharmaceuticals' shares soared 158% in pre-market trading to $4.21, reflecting strong investor interest in its oncology pipeline and signaling confidence in the company's growth potential.
- AI Integration: Recent regulatory approval for AI-based prescriptions in Utah highlights the strategic importance of Shuttle's use of the Molecule.ai platform in drug discovery, which is expected to reduce costs and accelerate the identification of new drug candidates.
- Pipeline Overview: The company's pipeline includes investigational candidates like Ropidoxuridine (ROPES) and SP-2, aimed at enhancing radiation therapy effectiveness and working alongside immunotherapies to strengthen tumor response, supporting precision medicine initiatives.
- Stock Performance History: SHPH has traded between $1.52 and $25.25 over the past year, with the latest data showing a closing price of $1.63 on January 16, 2026, up 10.14% from the previous day.
Shuttle Pharma Applauds Utah's AI Prescription Refill System, Enhancing Healthcare Efficiency
- AI Prescription Innovation: Utah becomes the first state in the U.S. to allow AI systems to authorize prescription refills without direct physician involvement, marking a significant advancement in reducing healthcare costs, eliminating delays, and expanding access to care.
- Enhanced Drug Discovery Efficiency: Shuttle Pharma's Molecule.ai platform applies AI technology to significantly shorten the time to identify viable drug candidates and reduce the costs of failed experiments, transforming what once took months of manual experimentation into just days, thereby greatly improving R&D efficiency.
- Regulatory and Safety Measures: The Molecule.ai platform incorporates uncertainty quantification and human-in-the-loop workflows to ensure expert oversight at critical decision points, enhancing the safety and reliability of AI in drug discovery.
- Future Policy Implications: Results from Utah's AI prescription pilot program will guide future state and federal AI policies, potentially serving as a national model for high-stakes AI regulation in healthcare, driving demand for robust AI platforms in the industry.
Shuttle Pharma Names Christopher Cooper as Acting CFO
CFO Resignation: Timothy Lorber has resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. effective November 21, 2025.
Interim CFO Appointment: Christopher Cooper, the current Interim Chief Executive Officer, has taken over the role of Chief Financial Officer.
Search for Permanent CFO: The company is actively searching for a permanent Chief Financial Officer to fill the position.
Disclaimer: The views expressed in the article do not necessarily reflect those of Nasdaq, Inc.
LexinFintech Shares Surge Over 15%; Check Out 20 Stocks Making Moves in Premarket Trading
LexinFintech Holdings Performance: LexinFintech Holdings Ltd reported a significant increase in quarterly earnings, rising to 43 cents per share from 28 cents a year ago, despite a drop in sales to $367.580 million from $521.851 million. The stock surged 15.3% in pre-market trading.
Other Gainers in Pre-Market Trading: Several stocks saw notable increases in pre-market trading, including Inspire Veterinary Partners Inc (+54.4%), VisionSys AI Inc (+43.4%), and JX Luxventure Group Inc (+36.2%).
Losers in Pre-Market Trading: Conversely, stocks like Clearside Biomedical Inc (-50.3%), Shuttle Pharmaceuticals Holdings Inc (-15%), and XChange TEC.INC (-14%) experienced significant declines in pre-market trading.
Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both gainers and losers, along with specific percentage changes.
What Caused the Overnight Surge in Shuttle Pharmaceuticals (SHPH) Stock?
Stock Performance: Shuttle Pharmaceuticals Holdings Inc. (SHPH) saw a 27.87% increase in after-hours trading, reaching $2.34, despite closing down 7.58% at $1.83 during regular trading. The stock is down 91.4% year-to-date.
S-1 Registration Statement: The company filed a Form S-1 registration statement with the SEC for the resale of 625,156 common shares linked to a pre-funded warrant with a $0.001 exercise price.
Private Placement: Shuttle Pharmaceuticals completed a private placement on November 4, generating approximately $2.5 million in gross proceeds from an accredited investor, with WestPark Capital Inc. acting as the placement agent.
Market Capitalization: As of Monday, the company had 1,603,285 outstanding shares and a market capitalization of $2.93 million, with the filing indicating that it will not receive proceeds from the selling stockholder’s share sales.
